Retatrutide Dosage Protocol (40 mg Vial)

Straightforward 12-week and 24-week planning for a 40 mg vial at 20 mg/mL.

• Retatrutide vials (40 mg each):
  • Phase 2, 12 weeks: Minimum 2 vials (56 mg required).
  • Phase 2, 24 weeks: Minimum 5 vials (200 mg required).
  • Phase 3, 12 weeks: Minimum 2 vials (48 mg required).
  • Phase 3, 24 weeks: Minimum 5 vials (180 mg required).
• U-100 insulin syringes (1 mL capacity):
  • Phase 2, 12 weeks: 12 new syringes.
  • Phase 2, 24 weeks: 24 new syringes.
  • Phase 3, 12 weeks: 12 new syringes.
  • Phase 3, 24 weeks: 24 new syringes.
• Bacteriostatic water (10 mL bottles):
  • Phase 2, 12 weeks: 1 bottle by volume (4 mL required).
  • Phase 2, 24 weeks: 1 bottle by volume (10 mL required).
  • Phase 3, 12 weeks: 1 bottle by volume (4 mL required).
  • Phase 3, 24 weeks: 1 bottle by volume (10 mL required).
• Alcohol swabs:
  • Phase 2, 12 weeks: 24 swabs minimum; 1 box of 100 covers the calculation.
  • Phase 2, 24 weeks: 48 swabs minimum; 1 box of 100 covers the calculation.
  • Phase 3, 12 weeks: 24 swabs minimum; 1 box of 100 covers the calculation.
  • Phase 3, 24 weeks: 48 swabs minimum; 1 box of 100 covers the calculation.

Sharps disposal: One appropriately sized container for used syringes.

Stability planning: Vial and diluent totals are minimum arithmetic quantities. Follow the exact product documentation for sterility, storage, handling loss, and discard timing.

Retatrutide 40 mg

View Supplier

U-100 syringes

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

Practice preparing this vial with the verified strength and final volume from this protocol.

• Reconstitute: Add 2 mL of bacteriostatic water to produce 20 mg/mL.
• Research frequency: Once weekly by subcutaneous administration in the cited human trials.^[1][3][5]
• Weekly research range: The cited programs evaluated target amounts through 12 mg weekly.^[1][2][3]
• Easy measuring: 1 U-100 unit = 0.01 mL = 200 mcg.
• Vial size: The 40 mg label is total nominal vial content, not a weekly amount.
• Vial coverage: At the 2 mg research stage, one vial supplies 20 full weekly amounts. At the 12 mg research stage, one vial supplies 3 full weekly amounts with 4 mg remaining. These are mass calculations, not vial storage or discard periods.

Research context and conversion details for a 40 mg Retatrutide vial at 20 mg/mL.

• Research route and frequency: The cited human trials used once-weekly subcutaneous administration.^[1][2][3][5]
• Studied target doses: Phase 2 included 1 mg, 4 mg, 8 mg, and 12 mg groups; phase 3 programs evaluated 4 mg, 9 mg, and 12 mg targets.^[1][2][3]
• 40 mg vial concentration: 40 mg divided by 2 mL equals 20 mg/mL.
• U-100 conversion: 1 unit equals 0.01 mL or 200 mcg at this concentration.
• Evidence boundary: Trial schedules describe investigated products, populations, and monitoring plans. They are not individualized dosing instructions.^[1][3][5][6]

The phase 2 and phase 3 schedules remain separate, while every row shows peptide mass, U-100 units, mL, and weekly frequency together.

• Phase 2 lower-start 12 mg arm: 2 mg, 4 mg, 8 mg, then 12 mg in four-week stages.^[1][10]
• Phase 3 12 mg target: 2 mg, 4 mg, 6 mg, 9 mg, then 12 mg in four-week stages.^[2][3]
• Other assigned targets: The trials included lower target groups; not every participant escalated to 12 mg.^[1][2][3][5]
• Measurement: At 20 mg/mL, the chart converts each researched weekly amount to units and mL.
• Strength consistency: Vial size changes concentration and yield, not the assigned research amount.

Storage and handling must follow the exact supplied formulation, diluent, and laboratory procedure.

• Before reconstitution: Keep the lyophilized vial dry, protected from light, and stored according to the exact product documentation.
• After reconstitution: Refrigerate only as the supplied formulation and diluent instructions permit.
• Label the vial: Record the 20 mg/mL concentration, reconstitution date, storage conditions, and documented discard date.
• Handling: Gently swirl or roll rather than shake, and avoid unnecessary agitation or repeated freeze-thaw cycles because peptide stability is formulation-dependent.^[16]

For this 40mg vial, adding 2 mL of bacteriostatic water determines the final concentration: 20 mg/mL. The conversion below explains how the reconstituted peptide maps to U-100 insulin-syringe markings and how many complete research amounts the vial contains.

• 2 mg: 0.10 mL or 10 units. One 40 mg vial contains 20 complete 2 mg amounts.
• 4 mg: 0.20 mL or 20 units. One vial contains 10 complete 4 mg amounts.
• 6 mg: 0.30 mL or 30 units. One vial contains 6 complete 6 mg amounts with 4 mg remaining.
• 8 mg: 0.40 mL or 40 units. One vial contains 5 complete 8 mg amounts.
• 9 mg: 0.45 mL or 45 units. One vial contains 4 complete 9 mg amounts with 4 mg remaining.
• 12 mg: 0.60 mL or 60 units. One vial contains 3 complete 12 mg amounts with 4 mg remaining. Vial-yield figures are arithmetic, not storage or discard periods.

This step-by-step reconstitution protocol uses the page's stated 2 mL volume. Reconstitute Retatrutide only under the governing laboratory procedure and the exact product documentation; Retatrutide remains an investigational peptide.^{[6][13][14][15]}

• Prepare: Wash hands, establish a clean work area, gather a sterile syringe and alcohol swabs, and clean the tops of the peptide vial and diluent vial. Allow the surfaces to dry.^[13][14][15]
• Add bacteriostatic water: Draw 2 mL, insert the needle into the 40 mg vial at an angle, and direct the liquid slowly down the glass wall rather than onto the powder cake.
• Dissolve gently: Gently swirl or roll the vial. Do not shake. Wait until the lyophilized powder has dissolved and inspect the solution according to the product documentation.
• Label and store: Label the vial with 20 mg/mL, the reconstitution date, and the documented storage and discard information. Refrigerate only as the exact formulation permits.
• Check the arithmetic: At 20 mg/mL, 1 U-100 unit is 200 mcg, 10 units is 2 mg, 20 units is 4 mg, and 60 units is 12 mg. Recompute every measurement if the water volume changes.
• Technique check: Use sterile technique, add the bacteriostatic water slowly against the vial wall, avoid air bubbles, and inspect the reconstituted peptide for visible particles. This peptide reconstitution workflow explains concentration and measurement; it does not establish a clinical dose.^{[13][14][15][16]}

Retatrutide dosing in published studies was organized by randomized target group and gradual escalation. The trial protocol determines the research schedule; the amount printed on a peptide vial does not.^[1][2][3][5]

• Phase 2 obesity trial: Participants were assigned to placebo or Retatrutide target groups of 1 mg, 4 mg, 8 mg, or 12 mg once weekly. Higher target groups used different starting and escalation approaches.^[1][10]
• Phase 2 type 2 diabetes trial: Multiple assigned Retatrutide doses and an active comparator were evaluated in a different population and endpoint framework.^[5][12]
• TRIUMPH phase 3 design: Once-weekly subcutaneous target doses were reached through planned four-week escalation stages.^[2]
• TRANSCEND-T2D-1: Adults with type 2 diabetes were evaluated in 4 mg, 9 mg, and 12 mg target groups.^[3]
• Protocol interpretation: The registered phase 2 study defines its tested population, product, and monitoring plan; it does not validate a separately manufactured research vial or a self-directed schedule.^[6]

Retatrutide is an investigational single-molecule agonist designed to activate GIP, GLP-1, and glucagon receptors. This triple-receptor profile is being studied for metabolic disease rather than treated as proof of a safe dose for an individual.^[4][7][8]

• GIP and GLP-1: Receptor activity contributes to glucose-dependent insulin signaling, appetite regulation, and nutrient-response pathways.
• Glucagon receptor: Agonist activity adds a distinct energy-expenditure and hepatic-signaling component to the research profile.
• Translational evidence: Preclinical and early clinical work describes receptor balance and the pharmacokinetic properties that supported once-weekly clinical-trial dosing.^[4]
• Evidence limits: Reviews of multi-receptor agonists explain the scientific rationale but do not establish an approved Retatrutide dosage.^[7][8]

Clinical findings must be interpreted by assigned target dose, population, follow-up period, formulation, and analysis plan. Results cannot be transferred automatically to a different product or research setting.

• Body-weight outcomes: The 48-week phase 2 obesity trial reported dose-related mean changes, with the largest average reduction in the 12 mg target group.^[1]
• Glycemic outcomes: The phase 2 type 2 diabetes trial reported changes in glycated hemoglobin and body weight across evaluated groups.^[5]
• Phase 3 evidence: TRANSCEND-T2D-1 reported glycemic and body-weight findings at 40 weeks in adults with type 2 diabetes.^[3]
• Liver-fat research: A randomized phase 2a substudy evaluated liver-fat change and metabolic dysfunction-associated steatotic liver disease outcomes.^[11]
• Cardiometabolic context: Cardiovascular and metabolic measures were secondary or exploratory outcomes and require population-specific interpretation.^[1][3][5][9]

Retatrutide is investigational. Safety findings remain specific to the studied populations, trial products, dose-escalation schedules, and clinical monitoring plans.^[1][3][5][6]

• Commonly reported events: Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation were among the most frequently reported events in the controlled trials.^{[1][3][5][12]}
• Escalation period: Gastrointestinal events were more frequent during dose escalation and were generally mild to moderate in the phase 2 obesity trial.^[1][10]
• Starting amount mattered: A lower 2 mg start improved gastrointestinal tolerability compared with a 4 mg start in the phase 2 obesity trial.^[1]
• Heart-rate observation: Dose-dependent increases were observed in phase 2 research and declined after peaking during follow-up.^[1][9]
• Product boundary: Clinical-trial findings do not establish purity, sterility, stability, or suitability of a separate research product. Follow the exact product documentation and institutional procedure.^[6][16]

These answers explain the 40 mg vial arithmetic and the evidence boundaries of this research protocol.

• How much BAC water is used in this page's calculation? The worked example adds 2 mL of bacteriostatic water to the 40 mg vial, producing 20 mg/mL. The exact product documentation and laboratory procedure govern the actual diluent and volume.
• How many units are in 1 mg? At 20 mg/mL, 1 mg occupies 0.05 mL, or 5 units on a U-100 syringe. A 2 mg amount is 10 units, while a 12 mg amount is 60 units.
• Is 40 mg a weekly dose? No. The 40 mg label is total nominal vial content. Published human trials assigned once-weekly research doses by protocol, independent of vial size.^[1][2][3][5]
• Does the 40 mg vial change dose escalation? No. A higher concentration changes the measurement and vial yield; it does not change the assigned trial schedule.
• Can a universal 28 days refrigerated rule be assumed? No. Do not infer a fixed storage or discard period from vial strength. Verify the exact formulation, diluent, preservative, cold-storage range, and product-specific discard instructions.^[16]
• What should be checked before measurement? Confirm the concentration, inspect the reconstituted solution under the governing procedure, and do not use a solution that is unexpectedly cloudy, shows cloudiness, or contains visible particles.

This page summarizes published human research schedules and the corresponding arithmetic for a 40 mg vial reconstituted with 2 mL. It is educational research information, not individualized medical advice or a recommendation for human use.

• 1
  New England Journal of Medicine (2023): Triple-Hormone-Receptor Agonist Retatrutide for Obesity: randomized phase 2 trial

  View Source
• 2
  Diabetes, Obesity and Metabolism (2026): TRIUMPH Phase 3 trial design, target doses, and escalation

  View Source
• 3
  The Lancet (2026): TRANSCEND-T2D-1 randomized phase 3 retatrutide trial

  View Source
• 4
  Cell Metabolism (2022): Discovery and translational pharmacology of LY3437943

  View Source
• 5
  The Lancet (2023): Retatrutide for type 2 diabetes: randomized phase 2 trial

  View Source
• 6
  ClinicalTrials.gov: Phase 2 retatrutide obesity study NCT04881760

  View Source
• 7
  Current Obesity Reports (2025): Triple agonism-based therapies for obesity

  View Source
• 8
  Nature Reviews Endocrinology (2024): Multi-receptor agonists for metabolic disease

  View Source
• 9
  Diabetes Care (2024): Incretin-based therapies and cardiovascular considerations

  View Source
• 10
  New England Journal of Medicine (2023): Supplementary material for the phase 2 obesity trial

  View Source
• 11
  Nature Medicine (2024): Retatrutide for metabolic dysfunction-associated steatotic liver disease: randomized phase 2a trial

  View Source
• 12
  The Lancet (2023): Supplementary data for the phase 2 diabetes trial

  View Source
• 13
  CDC: Subcutaneous administration guidance

  View Source
• 14
  Johns Hopkins Arthritis Center: How to give a subcutaneous injection

  View Source
• 15
  NCBI Bookshelf: Best practices for injections and related procedures

  View Source
• 16
  Journal of Pharmaceutical Sciences (2018): Stability considerations during freeze-thaw cycles

  View Source

Compare other Retatrutide vial strengths, dosage charts, and measurement guides without changing the underlying trial dose by vial size.